Abbott’s medical devices sales growth was led by double-digit growth in electrophysiology, diabetes care, neuromodulation, and structural heart. Credit: Michael Vi/Shutterstock.com.

Abbott has reported net earnings of $1.22bn in the first quarter of fiscal year 2024 (Q1 FY 2024), a 7% decrease from $1.31bn in the Q1 of fiscal year 2023 (FY 2023).

The company’s revenue for the first quarter that ended 31 March 2024 stood at $9.96bn, from $9.74bn in the same period of last year, driven by robust sales in medical devices.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

This reported sales growth of 2.2% includes the impact of the anticipated decline in Covid-19 testing-related sales compared to the previous year.

The company’s organic sales growth (excluding Covid-19 tests) for its underlying base business was 10.8%, representing the fifth consecutive quarter of double-digit growth.

The company reported a 14.2% increase in its worldwide medical devices sales on a reported basis and 14.3% on an organic basis in Q1 2024, including double-digit growth in both the US and internationally.

See Also:

Abbott noted that medical devices sales growth was led by double-digit growth in diabetes care, electrophysiology, neuromodulation, and structural heart.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s sales from Nutrition, Diagnostics, and Established Pharmaceuticals businesses stood at $2.06bn, $2.21bn, and $1.22bn, respectively.

For Q1 2024, on GAAP basis, diluted EPS was $0.70 and adjusted diluted EPS was $0.98, which does not include specified items.

On a GAAP basis, the company projects diluted earnings per share of $3.25 to $3.40 for the full year 2024.  

Abbott forecasts specified items for the full year of 2024 to be at $1.30 per share, primarily associated with intangible amortisation, restructuring, cost reduction initiatives, and other net expenses.

Excluding these specified items, the projected adjusted diluted earnings per share would be $4.55 to $4.70 for the full year.

In February 2024, the company’s board of directors announced a quarterly dividend of $0.55 per share, payable on 15 May 2024 to shareholders of record at the close of the business as of 15 April 2024.

Abbott chairman and CEO Robert B Ford said: “Our first-quarter results reflect a strong start to the year, and we are raising our full-year sales and EPS guidance.

“This was the fifth consecutive quarter that we delivered double-digit organic sales growth in our underlying base business, which included particularly strong results in Medical Devices and Established Pharmaceuticals.”

Recently, the US Food and Drug Administration (FDA) tagged a recall of Abbott’s HeartMate Touch System as Class I.